GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Cyclically Adjusted FCF per Share

Relmada Therapeutics (STU:4E2) Cyclically Adjusted FCF per Share : €-3.32 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Relmada Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.398. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-3.32 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-19), Relmada Therapeutics's current stock price is €2.76. Relmada Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-3.32. Relmada Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Relmada Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Relmada Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Cyclically Adjusted FCF per Share Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -2.35 -3.07 -2.90

Relmada Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 -3.18 -3.22 -2.90 -3.32

Competitive Comparison of Relmada Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Relmada Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Relmada Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Relmada Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.398/131.7762*131.7762
=-0.398

Current CPI (Mar. 2024) = 131.7762.

Relmada Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 -0.885 100.428 -1.161
201412 -1.148 99.070 -1.527
201503 -1.526 99.621 -2.019
201506 -1.490 100.684 -1.950
201509 -0.886 100.392 -1.163
201512 -1.270 99.792 -1.677
201603 -1.104 100.470 -1.448
201606 -0.843 101.688 -1.092
201609 -0.642 101.861 -0.831
201612 -0.458 101.863 -0.592
201703 -0.583 102.862 -0.747
201706 -0.297 103.349 -0.379
201709 -0.263 104.136 -0.333
201712 -0.305 104.011 -0.386
201803 -0.420 105.290 -0.526
201806 -0.621 106.317 -0.770
201809 -0.456 106.507 -0.564
201812 -0.433 105.998 -0.538
201903 -0.237 107.251 -0.291
201906 -0.394 108.070 -0.480
201909 -0.236 108.329 -0.287
201912 -0.330 108.420 -0.401
202003 -0.210 108.902 -0.254
202006 -0.287 108.767 -0.348
202009 -0.662 109.815 -0.794
202012 -0.350 109.897 -0.420
202103 -0.815 111.754 -0.961
202106 -0.838 114.631 -0.963
202109 -1.017 115.734 -1.158
202112 -1.745 117.630 -1.955
202203 -0.621 121.301 -0.675
202206 -0.683 125.017 -0.720
202209 -0.902 125.227 -0.949
202212 -1.125 125.222 -1.184
202303 -0.512 127.348 -0.530
202306 -0.407 128.729 -0.417
202309 -0.362 129.860 -0.367
202312 -0.312 129.419 -0.318
202403 -0.398 131.776 -0.398

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Relmada Therapeutics  (STU:4E2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Relmada Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (STU:4E2) Business Description

Industry
Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines